Here are four things to know.
1. QuintilesIMS analysts expects U.S. drug spending to jump 4 percent to 7 percent through 21, hitting $580 billion to $610 billion.
2. While analysts originally predicted an average spending growth of 6 percent to 9 percent, the company lowered its forecast due to fewer new drug approvals, increasing market competition and heightened scrutiny over prices.
3. When manufacturer discounts and rebates are considered, analysts expect spending to jump 2 percent to 5 percent through 2021, reaching $375 billion to $405 billion.
4. In 2016, prescription drug spending increased 5.8 percent from the year prior to $450 billion based on list prices. When adjusted for discounts and rebates, spending jumped 4.8 percent to $323 billion.
To view the full report, click here.
More articles on supply chain:
4 experts’ tips on modernizing hospital supply chains for the digital age
AstraZeneca wins FDA approval for immunotherapy drug
Physicians prescribe fewer branded drugs when hospitals limit drug rep interactions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.